STOKStoke Therapeutics, Inc.
Price
+7.9%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth fading, the market against it.
We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels. Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.
In the company’s own words · 10-K filed Mar 16, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Stoke Therapeutics, Inc. (STOK) reported revenue of $9.3M in Q2 2026 (quarter ended Jun 30, 2026), down 33% from the same quarter a year earlier. That came with net loss of $62M. For the full year FY2025, revenue was $184M (+405% year on year) and net income −$6.9M. Its largest product in Q1 2025 (quarter ended Mar 31, 2025) was IP License at $151M, 99% of the disclosed total, well ahead of Global Development Activity at 1.1%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 25, 2026On September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026.Director or officer change · Form 8-K
- Aug 3, 2026As previously disclosed, on May 20, 2022, Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which the Company may offer and sell shares (“Placement Shares”) of …Other event · Form 8-K
- Aug 3, 2026Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2025 · $152.4MThe company’s own SEC segment disclosure.
- IP License$150.8M99%
- Global Development Activity$1.6M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.